课题基金 / 基金详情

Studies on effects of KLEIP on cancer-progression

Studies on effects of KLEIP on cancer-progression
KLEIP 对癌症进展影响的研究
批准号:
20890145
负责人:
HARA Takahiko
金额:
$1.03万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Young Scientists (Start-up)
财政年份:
2008
资助国家:
日本
项目状态:
已结题
起止时间:
2008 至 2009

项目摘要

项目成果

HARA Takahiko的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Kelch-like ECT2-interacting protein (KLEIP) is a member of the kelch-related actin-binding proteins and was originally isolated as a binding partner of the ECT2 oncoprotein. ECT2 is a guanine nucleotide exchange factor for the Rho family of small GTPases, and is also a critical regulator of cytokinesis. KLEIP is involved in actin assembly at sites of cell-cell adhesion in MDCK cells. KLEIP also controls vascular endothelial growth factor-induced endothelial migration and sprouting angiogenesis. Therefore, KLEIP seems to have diverse functions in various situations. Since some kelch-related proteins have relationships with cancer cells and KLEIP can interact with ECT2, KLEIP may be involved in carcinogenesis. In this study, we found that KLEIP was localized to the Golgi complex in cultured urothelial cells, indicating that KLEIP is a novel trans-Golgi network- associated protein. Next, we examined the KLEIP expression levels in 71 available specimens, comprising 8 normal epithelial cells and 63 transitional cell carcinomas (TCCs). KLEIP expression was observed in 5 of 8 normal epithelial cells and 49 of 63 TCCs, respectively. The intensity of KLEIP expression varied among the samples. Further analyses indicated that the intensity of KLEIP expression was correlated with the tumor grade, but not with the T stage. Therefore, KLEIP could represent a novel biomarker for urothelial cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigation of developmental regulators for human hematopoietic stem cells and downstream road-blocker(s) of Lhx2
Molecular analysis of protein quality control system of the extraordinarily long-lived rodent
Characterization and exploration of bone marrow niche regulators for hematopoietic stem cells
Role of CXCL14 as a sensor for behavior-stimulating substance
国内基金
海外基金
AKR1C1抑制铁死亡途径调节膀胱尿路上皮癌中维迪西妥单抗治疗的敏感性研究
  • 批准号:
    2026JJ81335
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    王晶晶
  • 依托单位:
冷冻消融介导肿瘤相关巨噬细胞代谢重编程强化上尿路尿路上皮癌免疫治疗敏感性的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    陈艺凌
  • 依托单位:
恶性肿瘤精准诊治新技术和新策略研究-新型基于Nectin-4靶点CAR-NK细胞疗法的开发及其治疗晚期尿路上皮癌的应用研究
TGFB1诱导CAFs细胞分化通过T细胞耗竭导致尿路上皮癌不良预后的机制研究
  • 批准号:
    JCZRLH202501210
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位: